Acute Lymphoblastic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major acute lymphoblastic leukemia Markets reached a value of US$ 2,145.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4,003.7 Million by 2034, exhibiting a growth rate (CAGR) of 5.84% during 2024-2034.
The acute lymphoblastic leukemia market has been comprehensively analyzed in IMARC's new report titled "Acute Lymphoblastic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute lymphoblastic leukemia (ALL), also referred to as acute lymphocytic leukemia, is a type of blood and bone marrow malignancy, which is characterized by the development of a significant number of immature lymphocytes. Some of the common symptoms of ALL are frequent infections, bleeding from the gums, fever, severe nosebleeds, easy bruising, enlarged lymph nodes, etc. Other signs indicative of the disease include weakness, pale skin, shortness of breath, abdominal pain caused by a swollen liver or spleen, etc. The diagnosis of acute lymphoblastic leukemia typically involves a combination of laboratory investigations, including blood tests, bone marrow test, imaging tests, etc. Blood tests are used to identify abnormalities in the red blood cell count, white blood cell count, platelet count, and blast cell count. A bone marrow test is usually performed to look for specific changes in the cancer cells and ascertain whether the leukemia cells originated from B or T lymphocytes. Additionally, X-ray and computerized tomography (CT) scans can help assess if the cancer has spread to other parts of the body.
The rising prevalence of blood cancers and the inflating demand for advanced cancer therapeutics are primarily driving the acute lymphoblastic leukemia market. In addition to this, the emerging popularity of targeted therapies, such as monoclonal antibodies, which specifically target cancer cells, sparing healthy cells and reducing side effects, is further augmenting the market growth. Moreover, the escalating utilization of minimal residual disease (MRD) testing to identify patients who are at a high risk of relapse and adjust their treatment accordingly is also creating a positive outlook for the market. Apart from this, the widespread adoption of reduced-intensity conditioning regimens, which involves using lower doses of chemotherapy and radiation before the transplant, for older patients or those who may not tolerate high-dose chemotherapy, is further bolstering the market growth. Additionally, several key players are making extensive investments in exploring the use of gene editing to correct genetic mutations that cause ALL. This, in turn, is also acting as a significant growth-inducing factor. Besides this, numerous biotechnological advancements, including the development of new delivery methods, such as subcutaneous and oral formulations of existing therapies, for improving the effectiveness and convenience of treatment, are expected to drive the acute lymphoblastic leukemia market during the forecast period.
IMARC Group’s new report provides an exhaustive analysis of the acute lymphoblastic leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute lymphoblastic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute lymphoblastic leukemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute lymphoblastic leukemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute lymphoblastic leukemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute lymphoblastic leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute lymphoblastic leukemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute lymphoblastic leukemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute lymphoblastic leukemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acute lymphoblastic leukemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute lymphoblastic leukemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute lymphoblastic leukemia by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute lymphoblastic leukemia by type across the seven major markets?
How many patients are diagnosed (2018-2034) with acute lymphoblastic leukemia across the seven major markets?
What is the size of the acute lymphoblastic leukemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute lymphoblastic leukemia?
What will be the growth rate of patients across the seven major markets?
Acute Lymphoblastic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute lymphoblastic leukemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute lymphoblastic leukemia market?
What are the key regulatory events related to the acute lymphoblastic leukemia market?
What is the structure of clinical trial landscape by status related to the acute lymphoblastic leukemia market?
What is the structure of clinical trial landscape by phase related to the acute lymphoblastic leukemia market?
What is the structure of clinical trial landscape by route of administration related to the acute lymphoblastic leukemia market?
The acute lymphoblastic leukemia market has been comprehensively analyzed in IMARC's new report titled "Acute Lymphoblastic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute lymphoblastic leukemia (ALL), also referred to as acute lymphocytic leukemia, is a type of blood and bone marrow malignancy, which is characterized by the development of a significant number of immature lymphocytes. Some of the common symptoms of ALL are frequent infections, bleeding from the gums, fever, severe nosebleeds, easy bruising, enlarged lymph nodes, etc. Other signs indicative of the disease include weakness, pale skin, shortness of breath, abdominal pain caused by a swollen liver or spleen, etc. The diagnosis of acute lymphoblastic leukemia typically involves a combination of laboratory investigations, including blood tests, bone marrow test, imaging tests, etc. Blood tests are used to identify abnormalities in the red blood cell count, white blood cell count, platelet count, and blast cell count. A bone marrow test is usually performed to look for specific changes in the cancer cells and ascertain whether the leukemia cells originated from B or T lymphocytes. Additionally, X-ray and computerized tomography (CT) scans can help assess if the cancer has spread to other parts of the body.
The rising prevalence of blood cancers and the inflating demand for advanced cancer therapeutics are primarily driving the acute lymphoblastic leukemia market. In addition to this, the emerging popularity of targeted therapies, such as monoclonal antibodies, which specifically target cancer cells, sparing healthy cells and reducing side effects, is further augmenting the market growth. Moreover, the escalating utilization of minimal residual disease (MRD) testing to identify patients who are at a high risk of relapse and adjust their treatment accordingly is also creating a positive outlook for the market. Apart from this, the widespread adoption of reduced-intensity conditioning regimens, which involves using lower doses of chemotherapy and radiation before the transplant, for older patients or those who may not tolerate high-dose chemotherapy, is further bolstering the market growth. Additionally, several key players are making extensive investments in exploring the use of gene editing to correct genetic mutations that cause ALL. This, in turn, is also acting as a significant growth-inducing factor. Besides this, numerous biotechnological advancements, including the development of new delivery methods, such as subcutaneous and oral formulations of existing therapies, for improving the effectiveness and convenience of treatment, are expected to drive the acute lymphoblastic leukemia market during the forecast period.
IMARC Group’s new report provides an exhaustive analysis of the acute lymphoblastic leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute lymphoblastic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute lymphoblastic leukemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute lymphoblastic leukemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute lymphoblastic leukemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute lymphoblastic leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute lymphoblastic leukemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute lymphoblastic leukemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute lymphoblastic leukemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acute lymphoblastic leukemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute lymphoblastic leukemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute lymphoblastic leukemia by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute lymphoblastic leukemia by type across the seven major markets?
How many patients are diagnosed (2018-2034) with acute lymphoblastic leukemia across the seven major markets?
What is the size of the acute lymphoblastic leukemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute lymphoblastic leukemia?
What will be the growth rate of patients across the seven major markets?
Acute Lymphoblastic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute lymphoblastic leukemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute lymphoblastic leukemia market?
What are the key regulatory events related to the acute lymphoblastic leukemia market?
What is the structure of clinical trial landscape by status related to the acute lymphoblastic leukemia market?
What is the structure of clinical trial landscape by phase related to the acute lymphoblastic leukemia market?
What is the structure of clinical trial landscape by route of administration related to the acute lymphoblastic leukemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE LYMPHOBLASTIC LEUKEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE LYMPHOBLASTIC LEUKEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE LYMPHOBLASTIC LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 ACUTE LYMPHOBLASTIC LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE LYMPHOBLASTIC LEUKEMIA - UNMET NEEDS
10 ACUTE LYMPHOBLASTIC LEUKEMIA - KEY ENDPOINTS OF TREATMENT
11 ACUTE LYMPHOBLASTIC LEUKEMIA - MARKETED PRODUCTS
11.1 List of Acute Lymphoblastic Leukemia Marketed Drugs Across the Top 7 Markets
11.1.1 Blincyto (Blinatumomab) - Amgen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Asparlas (Calaspargase pegol) - Servier
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Kymriah (Tisagenlecleucel) - Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Besponsa (Inotuzumab ozogamicin) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Iclusig (Ponatinib) - Takeda
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACUTE LYMPHOBLASTIC LEUKEMIA - PIPELINE DRUGS
12.1 List of Acute Lymphoblastic Leukemia Pipeline Drugs Across the Top 7 Markets
12.1.1 TBI1501 - Takara Bio
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AUTO1 - Autolus
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Venetoclax - AbbVie/Genentech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 UCART 22 - Cellectis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 WUCART007 - Wugen
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ACUTE LYMPHOBLASTIC LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE LYMPHOBLASTIC LEUKEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE LYMPHOBLASTIC LEUKEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Lymphoblastic Leukemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Lymphoblastic Leukemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Lymphoblastic Leukemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Lymphoblastic Leukemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Lymphoblastic Leukemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Lymphoblastic Leukemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Lymphoblastic Leukemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Lymphoblastic Leukemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
16 ACUTE LYMPHOBLASTIC LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE LYMPHOBLASTIC LEUKEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE LYMPHOBLASTIC LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE LYMPHOBLASTIC LEUKEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE LYMPHOBLASTIC LEUKEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE LYMPHOBLASTIC LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 ACUTE LYMPHOBLASTIC LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE LYMPHOBLASTIC LEUKEMIA - UNMET NEEDS
10 ACUTE LYMPHOBLASTIC LEUKEMIA - KEY ENDPOINTS OF TREATMENT
11 ACUTE LYMPHOBLASTIC LEUKEMIA - MARKETED PRODUCTS
11.1 List of Acute Lymphoblastic Leukemia Marketed Drugs Across the Top 7 Markets
11.1.1 Blincyto (Blinatumomab) - Amgen
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Asparlas (Calaspargase pegol) - Servier
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Kymriah (Tisagenlecleucel) - Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Besponsa (Inotuzumab ozogamicin) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Iclusig (Ponatinib) - Takeda
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACUTE LYMPHOBLASTIC LEUKEMIA - PIPELINE DRUGS
12.1 List of Acute Lymphoblastic Leukemia Pipeline Drugs Across the Top 7 Markets
12.1.1 TBI1501 - Takara Bio
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AUTO1 - Autolus
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Venetoclax - AbbVie/Genentech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 UCART 22 - Cellectis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 WUCART007 - Wugen
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ACUTE LYMPHOBLASTIC LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE LYMPHOBLASTIC LEUKEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE LYMPHOBLASTIC LEUKEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Lymphoblastic Leukemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Lymphoblastic Leukemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Lymphoblastic Leukemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Lymphoblastic Leukemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Lymphoblastic Leukemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Lymphoblastic Leukemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Lymphoblastic Leukemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Lymphoblastic Leukemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Lymphoblastic Leukemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Lymphoblastic Leukemia - Access and Reimbursement Overview
16 ACUTE LYMPHOBLASTIC LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE LYMPHOBLASTIC LEUKEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE LYMPHOBLASTIC LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
